Fol. Biol. 2026, 72, 27-43
https://doi.org/10.14712/fb2026.0003
MiR-200a-5p Is a Potential Prognostic Marker for Lung Adenocarcinoma: Based on Transcriptomics, Bioinformatics, and In Vitro and In Vivo Experiments
Jiye Liu1,2,3
, Jiachun Li4, Yu Liu5
, Jiachun Li4, Yu Liu5
1Central Laboratory, Teaching Base of Huludao Central Hospital Affiliated to Jinzhou Medical University, 125000 Huludao, Liaoning, China
2Department of Family Medicine, Shengjing Hospital of China Medical University, 110000 Shenyang, Liaoning, China
3Department of Rehabilitation Medicine, Teaching Base of Huludao Central Hospital Affiliated to Jinzhou Medical University, 125000 Huludao, Liaoning, China
4Department of Pharmacy, Teaching Base of Huludao Central Hospital Affiliated to Jinzhou Medical University, 125000, Huludao, Liaoning, China
5Department of Science and Education, Teaching Base of Huludao Central Hospital Affiliated to Jinzhou Medical University, 125000 Huludao, Liaoning, China
Received April 2, 2025
Accepted January 7, 2026
References
1. , R., et al. (2022) Spatial mapping of cancer tissues by OMICS technologies. Biochim. Biophys. Acta Rev. Cancer 1877, 188663.
<https://doi.org/10.1016/j.bbcan.2021.188663>
2. , S. A., Hill, A. F. (2017) Analysis of miRNA signatures in neurodegenerative prion disease. Methods Mol. Biol. 1658, 67-80.
<https://doi.org/10.1007/978-1-4939-7244-9_6>
3. , P. R., Fallet, V., Sanchis-Borja, M. et al. (2021) Lung cancer is also a hereditary disease. Eur. Respir. Rev. 30, 210045.
<https://doi.org/10.1183/16000617.0045-2021>
4. , H., Huang, M., Zhang, D. et al. (2024) Metformin’s effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway. Front. Pharmacol. 15, 1477212.
<https://doi.org/10.3389/fphar.2024.1477212>
5. , T. A., Sottoriva, A. (2017) Measuring cancer evolution from the genome. J. Pathol. 241, 183-191.
<https://doi.org/10.1002/path.4821>
6. , M., Hibbard, J. C., Ma, E. et al. (2024) Targeting Wnt signaling for improved glioma immunotherapy. Front. Immunol. 15, 1342625.
<https://doi.org/10.3389/fimmu.2024.1342625>
7. , D. (2022) Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31-46.
<https://doi.org/10.1158/2159-8290.CD-21-1059>
8. , R., Manzoor, M., Hussain, A. (2022) Wnt signaling pathway: a comprehensive review. Cell Biol. Int. 46, 863-877.
<https://doi.org/10.1002/cbin.11797>
9. , Y., Bao, T., Li, Z. et al. (2020) Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells. Oncol. Lett. 20, 1256-1262.
<https://doi.org/10.3892/ol.2020.11649>
10. , M. F., Gonschorek, E., Massa, C. et al. (2020) Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. Oncoimmunology 9, 1774323.
<https://doi.org/10.1080/2162402X.2020.1774323>
11. , G., Fang, J., Wang, Y. et al. (2018) MiRNA-based therapeutic strategy in lung cancer. Curr. Pharm. Des. 23, 6011-6018.
<https://doi.org/10.2174/1381612823666170725141954>
12. , C., Shi, Q., Huang, X. et al. (2023) mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526-543.
<https://doi.org/10.1038/s41568-023-00586-2>
13. , Y-H., Chiu, C- H., Kuo, C-H., S. et al. (2021) Lung cancer in Republic of China. J. Thorac. Oncol. 16, 519-527.
<https://doi.org/10.1016/j.jtho.2020.10.155>
14. , Y., Yang, D., He, J. et al. (2016) Epidemiology of lung cancer. Surg. Oncol. Clin. N. Am. 25, 439-445.
<https://doi.org/10.1016/j.soc.2016.02.001>
15. Furtado, C. L., Dos Santos Luciano, M. C., Silva Santos, R. D. et al. (2019) Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics 14, 1164-1176.
<https://doi.org/10.1080/15592294.2019.1640546>
16. , R., Clevers, H. (2017) Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985-999.
<https://doi.org/10.1016/j.cell.2017.05.016>
17. , M. J., Tammela, T., Dow, L. E. (2021) WNT as a driver and dependency in cancer. Cancer Discov. 11, 2413-2429.
<https://doi.org/10.1158/2159-8290.CD-21-0190>
18. , E. Y., Clevers, H., Nusse, R. (2022) The Wnt pathway: from signaling mechanisms to synthetic modulators. Annu. Rev. Biochem. 91, 571-598.
<https://doi.org/10.1146/annurev-biochem-040320-103615>
19. , A., Singh, P., Jha, R. et al. (2023) Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma tumour microenvironment: implications for therapeutic intervention. Sci. Rep. 13, 16333.
<https://doi.org/10.1038/s41598-023-43484-1>
20. , A., Hassell, B. A., Ingber, D. E. (2019) Modelling cancer in microfluidic human organs-on-chips. Nat. Rev. Cancer 19, 65-81.
<https://doi.org/10.1038/s41568-018-0104-6>
21. , D. S., Cooper, G. M. (1991) Proto-oncogenes in development and cancer. Am. J. Reprod. Immunol. 25, 129-132.
<https://doi.org/10.1111/j.1600-0897.1991.tb01080.x>
22. , Z., Lazaris, A., Griniatsos, J. (2020) The prognostic significance of Caspase-3 and survivin expression in colorectal cancer patients. J. BUON 25, 2160-2170.
23. , H., Minegishi, K., Goto, A. et al. (2020) EphA2, a possible target of miR-200a, functions through the AKT2 pathway in human lung carcinoma. Int. J. Clin. Exp. Pathol. 13, 2201-2210.
24. , A., Rani, S. (2017) MiRNA biogenesis and regulation of diseases: an overview. Methods Mol. Biol. 1509, 1-10.
<https://doi.org/10.1007/978-1-4939-6524-3_1>
25. , L. H., Wu, C-F., Rajasekaran, N. et al. (2018a) Loss of tumour suppressor gene function in human cancer: an overview. Cell. Physiol. Biochem. 51, 2647-2693.
<https://doi.org/10.1159/000495956>
26. , X., Huang, S., Li, X. et al. (2018b) A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumours with papillary hyperplasia and papillary thyroid carcinoma. PLoS One 13, e0200290.
<https://doi.org/10.1371/journal.pone.0200290>
27. , Y., Qiu, C., Lu, N. et al. (2018c) FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. Int. J. Oncol. 52, 2130-2142.
28. , A., Braniewska, A., Kozar-Kamińska, K. (2017) MicroRNA in cardiovascular biology and disease. Adv. Clin. Exp. Med. 26, 865-874.
<https://doi.org/10.17219/acem/62915>
29. , F., Yang, J., Liu, J. et al. (2021) Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct. Target. Ther. 6, 218.
<https://doi.org/10.1038/s41392-021-00641-0>
30. , L., Luo, P., Song, Q. et al. (2018a) DNMT1/miR-200a/GOLM1 signaling pathway regulates lung adenocarcinoma cells proliferation. Biomed. Pharmacother. 99, 839-847.
<https://doi.org/10.1016/j.biopha.2018.01.161>
31. , T., Cao, C., Yang, J. et al. (2018b) miR-200a-5p regulates myocardial necroptosis induced by Se deficiency via targeting RNF11. Redox Biol. 15, 159-169.
<https://doi.org/10.1016/j.redox.2017.11.025>
32. , T., Liu, T., Cao, C. et al. (2019) miR-200a-5p augments cardiomyocyte hypertrophy induced by glucose metabolism disorder via the regulation of selenoproteins. J. Cell. Physiol. 234, 4095-4103.
<https://doi.org/10.1002/jcp.27206>
33. , X., Qu, X., Zhao, C. et al. (2019) FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling. FASEB J. 33, 10717-10730.
<https://doi.org/10.1096/fj.201900273R>
34. , Y., Xu, J., Luo, H. et al. (2022) Wnt signaling pathway in cancer immunotherapy. Cancer Lett. 525, 84-96.
<https://doi.org/10.1016/j.canlet.2021.10.034>
